Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

KLRA Other Non-current Liabilities

Long-term obligations not reported separately, such as lease or pension liabilities.

Kailera Therapeutics, Inc.NASDAQ: KLRA

Other Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Other non-current liabilities of $135K in Q2 FY2026

Q2 FY2026 other non-current liabilities was $135K.

Context

  • Other non-current liabilities amounted to 0.0% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$135K-100.0% QoQ
Last fiscal yearDec 2025
$992.63M— YoY
Other Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
992.63M USD
Year-over-year change
—

Other Non-current Liabilities vs competitors

How KLRA compares with its peers on the latest reported figures

  • KLRA's Jun 2026 other non-current liabilities of $135K is the 7th highest of the 10 companies compared; the peer median is $238K.
  • Other non-current liabilities amounts to 0.0% of total assets for KLRA, versus a peer median of 0.1%.
KLRA Competitors Peer median
Other Non-current Liabilities for KLRA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BMEABiomea Fusion, Inc.Mar 2026$18.37M ——39.6%
GUTSFractyl Health, Inc. Common StockMar 2026$6.92M +383.9%+349.2%7.0%
ALTAltimmune, Inc.Mar 2026$4.59M +15.9%+4.4%1.4%
BIOABioAge Labs, Inc.Mar 2026$477K +391.8%-85.9%0.1%
ORMPOramed Pharmaceuticals Inc.Mar 2026$238K +621.2%+56.4%0.1%
VTVTvTv Therapeutics Inc.Mar 2026$143K -1.4%-39.4%0.1%
KLRAKailera Therapeutics, Inc.Jun 2026$135K ——0.0%
VKTXViking Therapeutics, Inc.Jun 2026$0 ——0.0%
MBXMBX Biosciences, Inc. Common StockSep 2026$0 -100.0%-97.1%0.0%
NAMSNewAmsterdam Pharma Company N.V.Jun 2026$0 ——0.0%
Peer median (excluding KLRA) $238K+199.9%-17.5%0.1%

Competitors are the stored peer set for KLRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Intrinsic Alpha fair value

Locked

Current Price

$11.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.